Last updated on April 17, 2014 at 17:30 EDT

Latest Biogen Idec Canada Inc. Stories

2012-05-23 02:26:59

TORONTO, May 23, 2012 /CNW/ - Today Biogen Idec announced that Health Canada has approved a product monograph change for TYSABRI® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help...

2012-04-11 02:24:28

TORONTO, April 11, 2012 /PRNewswire/ - Today, Biogen Idec Canada announces that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription for patients living with multiple sclerosis (MS) in Canada.  Health Canada approved FAMPYRA on February 10, 2012 for the symptomatic improvement of walking in adult MS patients with walking disability (EDSS 3.5-7).(1) Walking impairment is one of the most common and disruptive consequences of MS(2) and...